Selected article for: "fever virus and human cell"

Author: Andersen, Petter I.; Krpina, Klara; Ianevski, Aleksandr; Shtaida, Nastassia; Jo, Eunji; Yang, Jaewon; Koit, Sandra; Tenson, Tanel; Hukkanen, Veijo; Anthonsen, Marit W.; Bjoras, Magnar; Evander, Magnus; Windisch, Marc P.; Zusinaite, Eva; Kainov, Denis E.
Title: Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
  • Cord-id: s0ci3r8w
  • Document date: 2019_10_18
  • ID: s0ci3r8w
    Snippet: Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in ce
    Document: Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FLUAV), niclosamide against HSV-2, brequinar against human immunodeficiency virus 1 (HIV-1), and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests.

    Search related documents:
    Co phrase search for related documents
    • long terminal and ltr long terminal repeat: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long terminal and ltr long terminal repeat promoter: 1, 2, 3, 4, 5, 6, 7, 8
    • long terminal and ltr promoter: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • long terminal and luciferase activity: 1
    • long terminal and luciferase assay: 1
    • long terminal and madison promega: 1
    • long terminal repeat and ltr long terminal repeat: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long terminal repeat and ltr long terminal repeat promoter: 1, 2, 3, 4, 5, 6, 7, 8
    • long terminal repeat and ltr promoter: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • long terminal repeat and luciferase activity: 1
    • long terminal repeat and luciferase assay: 1
    • long terminal repeat and madison promega: 1
    • ltr long terminal repeat and luciferase activity: 1
    • ltr long terminal repeat and luciferase assay: 1
    • ltr long terminal repeat and madison promega: 1
    • ltr long terminal repeat promoter and luciferase activity: 1
    • ltr long terminal repeat promoter and luciferase assay: 1
    • ltr promoter and luciferase activity: 1, 2
    • ltr promoter and luciferase assay: 1